# Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

Study · id `cardio:ct-nct05557942` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05557942](<https://clinicaltrials.gov/study/NCT05557942>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05557942

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 186 participants.

## Technical summary

Registry record NCT05557942. Randomized; quadruple masking; primary purpose treatment. Start 2022-11-02 (actual); primary completion 2024-08-08 (actual). Results posted on 2024-10-10.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 186 participants (enrolled count; ClinicalTrials.gov record NCT05557942, source copy `cardio:ctgov-nct05557942-2024-10-10`, retrieved 2026-10-31)
- Started: 2022-11-02 (actual) (ClinicalTrials.gov record NCT05557942, source copy `cardio:ctgov-nct05557942-2024-10-10`, retrieved 2026-10-31)
- Primary completion: 2024-08-08 (actual) (ClinicalTrials.gov record NCT05557942, source copy `cardio:ctgov-nct05557942-2024-10-10`, retrieved 2026-10-31)
- Completion: 2024-08-08 (actual) (ClinicalTrials.gov record NCT05557942, source copy `cardio:ctgov-nct05557942-2024-10-10`, retrieved 2026-10-31)
- Results first posted: 2024-10-10 (ClinicalTrials.gov record NCT05557942, source copy `cardio:ctgov-nct05557942-2024-10-10`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Canada; Chile; China; Colombia; France; Germany; Israel; Italy; Latvia; Mexico; Poland; Portugal; Singapore; South Africa; Spain; United Kingdom (ClinicalTrials.gov record NCT05557942, source copy `cardio:ctgov-nct05557942-2024-10-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05557942-2024-10-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
- Acronym: IMPAHCT-FUL
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): AV-101
- Lead sponsor: Aerovate Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: b5e4573770d0ac2c640e0b55d991c22e17d9a80d9820c66de3ced1a00bd391d2
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
